The antifungal pipeline: a reality check

Area of Science:

• Medical Mycology
• Infectious Diseases
• Drug Discovery

Background:

• Invasive fungal infections are increasing due to a larger immunocompromised population, including those with HIV and patients successfully treated for serious conditions.
• Current antifungal therapies (polyenes, flucytosine, azoles, echinocandins) show plateauing effectiveness and face challenges like toxicity and emerging drug resistance.
• There is a critical need for novel antifungal agents to address the growing threat of invasive fungal infections.

Purpose of the Study:

• To review the current landscape of antifungal drug development.
• To highlight novel targets, strategies, and compounds in the antifungal pipeline.
• To assess the potential outcomes of new antifungal therapies.

Main Methods:

• Comprehensive review of preclinical and pharmaceutical industry antifungal research.
• Analysis of emerging antifungal targets and therapeutic strategies.
• Evaluation of compounds in the development pipeline.

Main Results:

• The antifungal pipeline is robust and dynamic, featuring diverse approaches.
• Several novel compounds targeting different fungal pathways are advancing through development.
• The pipeline includes strategies to overcome existing drug resistance and toxicity issues.

Conclusions:

• The development of new antifungal drugs is crucial to combat rising infections and resistance.
• The current pipeline shows significant promise for future clinical applications.
• Continued research and development are essential to address the unmet needs in antifungal therapy.